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Abstract Thrombophilia can be identified in about half
of all patients presenting with VTE. Testing has increased
tremendously for various indications, but whether the
results of such tests help in the clinical management of
patients has not been settled. I use evidence from obser-
vational studies to conclude that testing for hereditary
thrombophilia generally does not alter the clinical man-
agement of patients with VTE, with occasional exceptions
for women at fertile age. Because testing for thrombophilia
only serves limited purpose this should not be performed
on a routine basis.
Keywords Thrombophilia  Venous thrombosis 
Pulmonary embolism
Over seventy years ago, Nygaard and Brown [1] used the
term thrombophilia to describe patients with an unex-
plained tendency for, mainly arterial, thrombotic events.
Egeberg [2] used the term in 1965, when he described a
Norwegian family that had a remarkable tendency to
venous thromboembolism (VTE), and discovered that this
was based on an inherited deficiency of antithrombin. In
the 80s of the last century, inherited deficiencies of protein
C and protein S were described [3, 4]. Since then various
laboratory abnormalities, both hereditary and acquired,
have been discovered that increase the risk of VTE. The
most prevalent and relatively strong genetic risk factors are
gain-of-function mutations, i.e. factor V Leiden that causes
resistance to protein C (activated protein C, APC resis-
tance) [5–7], and the prothrombin 20210A mutation that
leads to higher levels of prothrombin [8]. Nowadays,
inherited thrombophilia can be identified in about half of
all patients presenting with VTE, and appears to provide at
least a partial explanation for a previously poorly explained
disease [9]. Over the past decades, testing has increased
tremendously for various indications [10], but whether the
results of such tests help in the clinical management of
patients has not been settled [11, 12]. Here, I present an
evidence-based approach for the most commonly tested
inherited thrombophilias, i.e., deficiencies of antithrombin,
protein C, or protein S, and the factor V Leiden and pro-
thrombin G20210A mutations. In such an approach, more
important than the strengths of their associations with VTE
and its inherent absolute risks, is how testing for throm-
bophilia is able to reduce these risks.
Mechanisms of thrombophilia
The currently established inherited thrombophilias impact
either the procoagulant or anticoagulant pathways. A sim-
plified scheme of coagulation and fibrinolysis is depicted in
the Fig. 1. Antithrombin, protein C and protein S are key
players in the regulation of coagulation, hence they are
referred to as natural anticoagulants. Antithrombin down-
regulates thrombin, and activated protein C, together with
its cofactor protein S, inactivates factors Va and VIIIa.
Factor V Leiden refers to a point mutation in the gene at
position 1691, leading to a replacement of arginine (Arg) by
glutamine (Gln) at amino acid position 506 of the factor Va
protein, making it less susceptible for cleavage by activated
protein C at this important site. The prothrombin 20210A
mutation leads to a normal protein, but at higher levels.
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Thrombophilia testing for patients with venous
thromboembolism
Thrombophilia testing is most often considered in patients
with VTE, particularly if they are young, have recurrent
episodes, have thrombosis at unusual sites, or have a
positive family history for the disease. However, although
such a strategy may lead to an increased yield of testing,
the main question is whether a positive test result alters
management. In general, VTE has a tendency to recur, with
a cumulative incidence of a second episode of approxi-
mately 30% in 8 years [13]. Patients with a well recognized
and transient clinical risk factor such as surgery, eliciting a
first VTE have a very low risk of recurrence [13–15].
However, whether the presence of thrombophilia is able to
predict recurrence is much less clear, with conflicting
results in various studies that compared the prevalences of
thrombophilia in patients with recurrent VTE with those in
patients without recurrence [12]. A randomized controlled
trial in which testing for thrombophilia in patients with a
first episode of VTE is the intervention, and recurrent VTE
is the outcome, would be ideal. Testing should then lead to
a predefined strategy to prevent recurrence, with for
instance a longer or indefinite duration of anticoagulant
therapy. To my knowledge, no such trials have been suc-
cessfully performed [11, 16].
Several follow-up studies have assessed the risk of
recurrent VTE associated with thrombophilic defects. In a
cohort of patients from Cambridge, those with a thromb-
ophilic defect, including antithrombin, protein C, or protein
S deficiency (HRs ranging from 1.0 to 2.9 for individual
deficiencies, which were almost all combined with other
thrombophilic defects), or the factor V Leiden mutation
(HR 1.4, 95% CI 0.7–2.8), or the prothrombin 20210A
mutation (HR 1.7, 95% CI 0.5–5.6), were not at highly
increased risk of developing a recurrent venous thrombotic
event [14]. In the Leiden Thrombophilia (LETS) study, no
clearly increased risk of recurrent VTE was found for the
prothrombotic mutations: factor V Leiden (HR 1.3, 95% CI
0.8–2.1), or prothrombin 20210A mutation (HR 0.7, 95%
CI 0.3–2.0) [15]. A mildly increased risk of recurrent VTE
was found in patients with a deficiency in one of the
anticoagulants protein C, protein S, or antithrombin (HR
1.8; 95% CI 0.9–3.7). An Italian cohort study reported a
similar risk increase of recurrence associated with defi-
ciencies of the anticoagulants (antithrombin deficiency: HR
1.9, 95% CI 1.0–3.9, protein C or S deficiency: HR 1.4,
95% CI 0.9–2.2) [17]. In a large pooled study of
Fig. 1 Blood Coagulation and Fibrinolysis Simplified scheme of
coagulation and fibrinolysis. Coagulation is initiated by a tissue factor
(TF)—factor VIIa complex that can activate factor IX or factor X,
leading to formation of the key enzyme thrombin (factor IIa). Tissue
factor–dependent coagulation is rapidly inhibited by tissue factor–
pathway inhibitor (TFPI). Coagulation is maintained through the
activation by thrombin of factor XI. Through the intrinsic tenase
complex (factors IXa and VIIIa) and the prothrombinase complex
(factors Xa and Va), the additional thrombin required to down-
regulate fibrinolysis is generated by the activation of thrombin-
activatable fibrinolysis inhibitor (TAFI). The coagulation system is
regulated by the protein C pathway. Thrombin activates protein C in
the presence of thrombomodulin. Together with protein S (PS),
activated protein C (APC) is capable of inactivating factors Va and
VIIIa, which results in a down-regulation of thrombin generation and
consequently in an up-regulation of the fibrinolytic system. The
activity of thrombin is controlled by the inhibitor antithrombin (AT).
The solid arrows indicate activation and the broken arrows inhibition
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thrombophilic families, we observed a cumulative inci-
dence of VTE recurrences after 10 years of 55% in rela-
tives with a deficiency of antithrombin, protein C or protein
S deficiency, as compared to 25% in those with the factor
V Leiden mutation, the prothrombin mutation or high
levels of FVIIIa [18].
In order to investigate whether testing for thrombophilia
reduces the risk of recurrent VTE in patients with a first
episode of thrombosis, for instance by management alter-
ations (such as prolonged use of anticoagulations, avoid-
ance of or intensified prophylaxis in high risk situations)
we selected 197 patients from the MEGA case control
study who had had a recurrent event during follow-up [19].
We compared the proportion of these patients who had
been tested with the proportion of 324 patients who did not
have a recurrence during follow-up, matched for age, sex,
year of event and geographical region. Thrombophilia tests
were performed in 35% of cases and in 30% of controls.
The OR for recurrence was 1.2 (95% CI 0.9–1.8) for tested
versus non-tested patients, indicating that testing does not
reduce the risk of recurrent VTE in patients who have
experienced a first episode.
In conclusion, observational studies show that patients
who have had VTE and have hereditary thrombophilia,
are at most at a slightly increased risk for recurrence.
Furthermore, in real life, no beneficial effect on the risk
of recurrent VTE was observed in patients who had been
tested for thrombophilia. In general, after a first episode
of venous thrombosis, 3–6 months of anticoagulant
therapy is considered to have the optimal balance
between the risk of treatment (bleeding) and the benefit
(prevention of an extension or recurrence of venous
thrombosis) [20]. In the absence of trials that compared
routine and prolonged anticoagulant treatment in patients
testing positive for thrombophilia, prolonged anticoagu-
lant therapy cannot be justified as it may cause more
harm than benefit.
Testing for thrombophilia to modify the risk
of a first deep venous thrombosis
The risk of VTE in individuals with thrombophilia is, by
definition, increased as compared to the general population.
In clinical practice, requests to estimate the risk of a first
episode of VTE are most often done by asymptomatic
individuals with a family history of VTE, with or without a
known specific thrombophilic defect. It is important to
realize that having a family history of VTE increases the
risk of VTE in a first degree relative by approximately two-
fold, regardless of the presence of a known hereditary
thrombophilic defect [21]. Still, a potential advantage of
testing patients with VTE for thrombophilia may be the
identification of asymptomatic family members of
thrombophilic patients in order to take preventive measures
if tested positive.The risks of a first episode of VTE have
been assessed in several family studies with similar design
and are summarized in Table 1.
Although antithrombin deficiency has historically been
regarded to be the most severe thrombophilic defect lead-
ing to a very high risk of thrombosis, in a large population
based case–control study antithrombin deficiency (mea-
sured as plasma levels \80 U/dl on two occasions) was
associated with a fivefold (95% CI 0.7–34) increased risk
of a first deep venous thrombotic event.(22) Retrospective
and prospective studies in families with at least one pro-
band with VTE and antithrombin deficiency found an
incidence of first VTE between 0.4% and 1.7% per year in
deficient relatives [23–27]. Also for the other hereditary
thrombophilias, the overall absolute risk of VTE in
asymptomatic relatives has been assessed in numerous
studies and is generally low, even during high risk situa-
tions such as pregnancy, the postpartum period, surgery,
immobilisation, trauma and during the use of oral contra-
ceptives [23, 27–37] (Table 1). Noteworthy, the risk esti-
mates related to surgery, trauma and immobilisation as
Table 1 Estimated incidence of a first episode of venous thrombosis in carriers of various thrombophilic defects
Antithrombin, protein C,
or protein S deficiency










Overall (%/year, 95% CI) 1.5 (0.7–2.8) 0.5 (0.1–1.3) 0.4 (0.1–1.1) 1.8 (0.1–4.0)a
Surgery, trauma, or immobilization
(%/episode, 95% CI)
8.1 (4.5–13.2) 1.8 (0.7–4.0) 1.6 (0.5–3.8) –
Pregnancy (%/pregnancy, 95% CI) 4.1 (1.7–8.3) 2.1 (0.7–4.9) 2.3 (0.8–5.3) 16.3b
During pregnancy, %, 95% CI 1.2 (0.3–4.2) 0.4 (0.1–2.4) 0.5 (0.1–2.6) 7.0b
Postpartum period, %, 95% CI 3.0 (1.3–6.7) 1.7 (0.7–4.3) 1.9 (0.7–4.7) 9.3b
Oral contraceptive use (%/year of use, 95% CI) 4.3 (1.4–9.7) 0.5 (0.1–1.4) 0.2 (0.0–0.9) –
Data apply to individuals with at least one symptomatic first-degree relative
a Based on pooled OR of 18 [8–40] and an incidence of 0.1% in non-carriers
b Data from family studies, risk estimates lower in other settings
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shown in this table for a large part reflect the situation
before standard prophylaxis was routine patient care.
It is clear that the 2% annual major bleeding risk asso-
ciated with continuous anticoagulant treatment outweighs
the risk of venous thrombosis [38, 39].
For women at fertile age who wish to use oral contra-
ceptives, or have an increased risk of VTE during and after
pregnancy, Tables 2, 3 indicate the effect of either avoid-
ance of these risk factors (for oral contraceptives), or tak-
ing preventing measures during and/or after pregnancy.
The risk of additional venous thrombotic events induced by
the use of oral contraceptive is outlined in Table 2, and can
be applied to women who have a positive first degree rel-
ative with VTE who has a known thrombophilic defect.
The values clearly indicate that women with antithrombin,
protein C or protein S deficiency have a high risk of VTE
provoked by use of oral contraceptives, and that it may be
worthwhile to test women from these families to advise
those with a deficiency to avoid use of the contraceptive
pill. However, it should be noted that women without a
deficiency still have a markedly increased risk of oral
contraceptive related VTE compared to the general popu-
lation (0.7 vs. 0.03% per year of use), probably because of
co-segregation of yet unknown thrombophilias. Thus, a
negative thrombophilia test may lead to false reassurance.
These risk estimates are very different for the more com-
mon thrombophilias such as factor V Leiden, with a large
number of women needing to avoid use of oral contra-
ceptives to avoid 1 VTE, and a number needed to test of
666. Table 3 indicates the number needed to test to install
prophylactic measurements around pregnancy, again
applicable to women from thrombophilic families. Only for
women with antithrombin, protein C or protein S defi-
ciency, or those who are homozygous for factor V Leiden,
the risks during pregnancy may outweigh the nuisance of
daily subcutaneous low-molecular-weight heparin injec-
tions and skin reactions, and the very small risk for severe
complications of anticoagulant therapy during pregnancy
[40–42]. Whether the 80% of pregnancy-related episodes
occurring in the 6–12 weeks postpartum justifies prophy-
laxis during this period is a matter of the physicians’ and
patients’ preference in which the values from Table 3 can
be useful. It is noteworthy that in these family studies the
risk of pregnancy-related VTE in women who do not have
the thrombophilic defect is approximately 0.5%, a value in
the same range as in the general population [43]. Hence,
withholding prophylaxis to women from thrombophilic
families who do not have the defect is supported by
evidence.
In conclusion, only in limited situations thrombophilia
testing in asymptomatic relatives may be useful. This
seems particularly the case in families with antithrombin,
protein C or protein S deficiency, or homozygosity for
factor V Leiden, and appears limited to women who intend
to become pregnant and perhaps, in individual cases of
women who would like to use oral contraceptives. In
general, appropriate counselling with knowledge of abso-
lute risks should help in making an informed decision in
which patient’s preferences can be taken into account.
Thrombophilia testing for other clinical indications
Although numerous studies have investigated the associ-
ation between thrombophilia and arterial cardiovascular
diseases, positive and negative studies are equally avail-
able [44]. There is no evidence that the presence of
inherited thrombophilia should lead to different secondary
prevention, and testing in this clinical setting is not
justified.
Table 2 Estimated number of asymptomatic thrombophilic women who should avoid using oral contraceptives to prevent one VTE, and
estimated number needed to test





OC to prevent 1 VT
N of female
relatives to be tested
Antithrombin, protein C, or protein S deficiency
Deficient relatives 4.3a 3.6 28 56
Non-deficient relatives 0.7a
Factor V Leiden or prothrombin mutation
Relatives with the mutation 0.5a 0.3 333 666
Relatives without the mutation 0.2a
Family history of VTE
General population, no family history 0.03b 0.02 5000 None
General population, positive family history 0.06b 0.04 2500 None
a Based on family studies as outlined in Table 1
b Based on a population baseline risk of VTE in young women of 0.01% per year [64], a relative risk of VTE by use oral contraceptives of three
[65], and a relative risk of two of VTE by having a positive family history [21]
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Inherited thrombophilia has also been implicated in
pregnancy complications, such as recurrent miscarriage
and fetal death, analogous to the clinical manifestations
that are part of the antiphospholipid syndrome [45]. The
association between hereditary thrombophilia varies
depending on type of thrombophilia and timing of preg-
nancy failure [46], and there is a modest association also
between thrombophilia and other adverse pregnancy out-
comes, most notably preeclampsia and intra-uterine growth
retardation [47]. However, whether this association can be
considered causal remains controversial, as many other
factors play a role in the risk of pregnancy complications
[48–51]. Therapeutic options to prevent pregnancy com-
plications in women with thrombophilia comprise aspirin
as well as (low-molecular-weight) heparin. For women
with recurrent pregnancy loss, there is no evidence sup-
porting treatment [50, 52]. Observational research is
hampered by severe methodological flaws or inconsistent
results. Two randomized trials have not used an adequate
comparator, i.e. no treatment or placebo [53, 54]. Two
recent randomized controlled trials in women with unex-
plained recurrent miscarriage, the ALIFE study from The
Netherlands and the SPIN study from Scotland, were
unable to demonstrate a beneficial effect of anticoagulant
therapy, compared to no pharmacological treatment or
placebo [55, 56]. Although the ALIFE study was under-
powered for subgroup analyses, an a priori planned anal-
ysis in women with inherited thrombophilia showed a
relative risk for live birth of 1.31 (95% CI 0.74–2.33) for
the combined intervention compared to placebo, and 1.22
(95% CI 0.69–2.16) for aspirin, with corresponding abso-
lute difference in live birth rates of 16.3% (95% CI -18.2
to 50.8) and 11.8% (95%CI -21.1 to 44.6) respectively
[55]. The possibility that one or both of these interventions
might be beneficial in such women warrants further study
in adequately powered, controlled trials. With the current
evidence, using anticoagulant therapy to improve the
prognosis of a pregnancy in women with pregnancy com-
plications should be considered experimental.
Drawbacks of thrombophilia testing
Disadvantages of testing patients with a venous thrombosis
for thrombophilia might be the high costs of testing [57].
Although some cost-effectiveness studies have been pub-
lished on the topic of testing for thrombophilia, which
concluded that in some scenarios testing could indeed
be cost-effective, the number of assumptions from incon-
sistent observational studies seriously hamper their
interpretation [58, 59]. The psychological impact and
consequences of knowing to be a carrier of a (genetic)
thrombophilic defect is a potential drawback of testing
[60]. Most studies that focused on impact of testing for
thrombophilia showed that patients had experienced low
psychological distress following thrombophilia testing [61,
62]. Nevertheless, a qualitative study described several
negative effects of both psychological and social origin
[63]. Finally, difficulties in obtaining life or disability
insurances are frequently encountered by individuals who
are known carriers of thrombophilia, regardless whether
they are symptomatic or asymptomatic [63].
Conclusions
Despite the increasing knowledge about the etiology of
venous thrombosis, testing for hereditary thrombophilia
generally does not alter the clinical management of patients
with VTE. There are a few exceptions. For some asymp-
tomatic women at fertile age who come from families with
a tendency for VTE and a known thrombophilic defect, a
positive test may lead to the decision to install prophylaxis
during or postpartum in case of pregnancy, or the indi-
vidual decision to not use oral contraceptives.
In conclusion, because testing for hereditary thrombo-
philia does not affect clinical management of most patients
with VTE, it only serves limited purpose and should not be
performed on a routine basis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Table 3 Estimated number of asymptomatic thrombophilic women
who should use LMWH prophylaxis during pregnancy and/or the
postpartum period to prevent pregnancy-related VTE, and estimated
number needed to test
Thrombophilia N of female relatives to
be tested to prevent
VTE during pregnancya
N of female relatives















a Based on family studies as outlined in Table 1
These estimates apply to women with a positive family history of
VTE and assume a 100% efficacy of prophylaxis with LMWH
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